APPLICATIONS / DATABASESSUPPLEMENTAL DATAFACULTYMIRROR SITESCOLLABORATIVE PROJECTSDEPARTMENTS
 
Supplementary Information for:

Identification of genes associated with chemotherapy cross-resistance and treatment response in childhood acute lymphoblastic leukemia.

Sanne Lugthart 1,2,6,8 , Meyling H. Cheok 1,2,8 , Monique L. den Boer 6 , Wenjian Yang 1,2,5 , Amy Holleman 6 , Cheng Cheng 3 , Ching-Hon Pui 1,4,5 , Mary V. Relling 1,2,5 , Gritta E. Janka-Schaub 7 , Rob Pieters 6,9 , William E. Evans 1,2,5,9

1 Hematological Malignancy Program
2 Department of Pharmaceutical Sciences
3 Department of Biostatistics
4 Department of Hematology-Oncology ,St. Jude Children's Research Hospital , Memphis , USA
5 The Pharmacogenetics of Anticancer Agents Research Group in the Pharmacogenetics Research Network, Memphis , Tennessee , USA
6 Department of Pediatric Oncology/Hematology ,Erasmus University Medical Center/Sophia Children's Hospital, ,Rotterdam , The Netherlands
7 COALL study group ,Children's University Hospital , Hamburg , Germany
8 These first authors contributed equally to this work.
9 These last authors contributed equally to this work.

Supplemental Figure 3: Distribution of LC50 values for each drug tested in the CR-group and VCR-ASP group analyzed for gene expression.

In each plot, the LC50 values (n=129) for each drug are plotted on the x-axis [prednisolone (PRD), vincristine (VCR) and daunorubicin (DNR) in µg/ml; asparaginase (ASP) in IU/ml] and the percentage of patients in each range of LC50 values is plotted on the y-axis. A. The distribution of LC50 values for each drug; red indicates ALL classified based on CR-score as cross-resistant (n=29), gray as intermediate (n=62) and green as cross-sensitive (n=38). B. The distribution of LC50 values for VCR and ASP; blue indicates VCR-sensitive plus ASP-resistant ALL based on the VCR-ASP-score (n=42), orange indicates VCR-resistant plus ASP-sensitive ALL (n=34), and the remaining patients are indicated in gray (n=53).